{"analyses":[{"ciLowerLimit":"1.58","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"13.60","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.005","paramType":"Odds Ratio (OR)","paramValue":"4.63","statisticalMethod":"Regression, Logistic"},{"ciLowerLimit":"4.72","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"35.44","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","paramType":"Odds Ratio (OR)","paramValue":"12.94","statisticalMethod":"Regression, Logistic"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.0","upperLimit":"6.4","value":"2.6"},{"groupId":"OG001","lowerLimit":"6.9","upperLimit":"16.8","value":"10.9"},{"groupId":"OG002","lowerLimit":"18.5","upperLimit":"29.3","value":"23.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"156"},{"groupId":"OG001","value":"156"},{"groupId":"OG002","value":"234"}],"units":"Participants"}],"description":"SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score, as developed by the National Alopecia Areata Foundation Working Committee. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process. The SALT score will range from 0% to 100%, with lower score indicating better health outcomes. SALT50 indicates at least a 50 % improvement from baseline in the SALT score.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received two placebo tablets matched to baricitinib, administered orally QD to maintain the blind.","id":"OG000","title":"Placebo"},{"description":"Participants received one 2 mg Baricitinib tablet administered orally QD and one placebo tablet administered orally QD to maintain the blind.","id":"OG001","title":"2 mg Baricitinib"},{"description":"Participants received one 4 mg Baricitinib tablet and one placebo tablet administered orally QD to maintain the blind.","id":"OG002","title":"4 mg Baricitinib"}],"paramType":"NUMBER","populationDescription":"All randomized participants who had evaluable data for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Week 12","title":"Percentage of Participants Achieving 50% Improvement of Severity of Alopecia Tool (SALT50)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}